PL
NKTR icon

Parkwood LLC’s Nektar Therapeutics NKTR Stock Holding History

Parkwood LLC’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-1,662
Closed -$312K – 536
2015
Q2 		$312K Buy
1,662
+632
+61% +$109K 0.04% 369
2015
Q1 		$170K Buy
+1,030
New +$212K 0.02% 447

Other funds holding NKTR

O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Parkwood LLC's NKTR Position: Q3 2015 in Review

Parkwood LLC sold out of Nektar Therapeutics (NKTR) in Q3 2015, closing a stake of 1,662 shares — an estimated $312K sold.

Parkwood LLC first reported a position in NKTR in Q1 2015 and held it in 2 quarters. The position peaked at $312K in Q2 2015. 166 funds tracked by Wall St. Rank hold NKTR as of Q3 2015.

  • Parkwood LLC reported no remaining Nektar Therapeutics position as of Q3 2015 after selling out during the quarter.
  • Parkwood LLC sold 1,662 Nektar Therapeutics shares in Q3 2015, an estimated $312K.
  • Parkwood LLC first reported a position in Nektar Therapeutics in Q1 2015 and held it in 2 quarters.
  • Parkwood LLC's Nektar Therapeutics position peaked at $312K in Q2 2015.
  • 166 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2015.

Based on Parkwood LLC's 13F filing for Q3 2015, filed 23 Oct 2015.